RESUMO
MSC (mesenchymal stromal cells) can differentiate into renal adult cells, and have anti-inflammatory and immune-modulating activity. In the present study, we investigated whether MSC have protective/reparative effects in anti-Thy1 disease, an Ab (antibody)-induced mesangiolysis resulting in mesangioproliferative nephritis. We studied five groups of rats: (i) rats injected with anti-Thy1.1 Ab on day 0 (group A); (ii) rats injected with anti-Thy1.1 Ab on day 0+MSC on day 3 (group B); (iii) rats injected with anti-Thy1.1 Ab on day 0+mesangial cells on day 3 (group C); (iv) rats injected with saline on day 0+MSC on day 3 (group D); and (v) rats injected with saline on day 0 (group E). Rats were killed on days 1, 3, 7 and 14. MSC prevented the increase in serum creatinine, proteinuria, glomerular monocyte influx and glomerular histopathological injury. Furthermore, MSC suppressed the release of IL-6 (interleukin-6) and TGF-ß (transforming growth factor-ß), modulated glomerular PDGF-ß (platelet-derived growth factor-ß), and reset the scatter factors and their receptors, potentiating HGF (hepatocyte growth factor)/Met and inactivating MSP (macrophage-stimulating protein)/Ron (receptor origin nantaise). Few MSC were found in the kidney. These results indicate that MSC improve anti-Thy 1 disease not by replacing injured cells, but by preventing cytokine-driven inflammation and modulating PDGF-ß and the scatter factors, i.e. systems that regulate movement and proliferation of monocytes and mesangial cells.
Assuntos
Citocinas/metabolismo , Glomerulonefrite/terapia , Fator de Crescimento de Hepatócito/metabolismo , Transplante de Células-Tronco Mesenquimais/métodos , Células Estromais/transplante , Animais , Células Cultivadas , Complemento C3/metabolismo , Glomerulonefrite/imunologia , Glomerulonefrite/metabolismo , Glomerulonefrite/patologia , Proteínas de Fluorescência Verde/metabolismo , Mediadores da Inflamação/metabolismo , Masculino , Ratos , Ratos Sprague-Dawley , Ratos Transgênicos , Receptores Proteína Tirosina Quinases/metabolismo , Antígenos Thy-1/imunologiaRESUMO
A promising way to increase the number of kidneys for transplantation is to expand the donor pool by including non-heart-beating donors (NHBDs). The centers involved in NHBD transplantation programs have reported a 16-40% increase in kidney transplants. A key issue with NHBD is the significantly higher rate of delayed graft function (DGF) and primary non-function (PNF) compared with that associated with heart-beating donor (HBD) transplants. However, although transplants from NHBD are associated with a greater incidence of early adverse events, long-term graft survival appears to be similar to that observed after transplants from HBDs. In addition, the use of extracorporeal membrane oxygenation and mechanical perfusion, the careful selection of recipients and donors, and an adequate therapeutic strategy may at least partially reduce the risk of PNF and DGF and improve transplant outcome.
Assuntos
Parada Cardíaca , Transplante de Rim , Coleta de Tecidos e Órgãos , Obtenção de Tecidos e Órgãos/métodos , Morte Encefálica , Função Retardada do Enxerto , Sobrevivência de Enxerto , Humanos , Itália , Falência Renal Crônica/cirurgia , Transplante de Rim/mortalidade , Preservação de Órgãos/métodos , Fatores de Risco , Fatores de Tempo , Resultado do TratamentoRESUMO
Sibutramine, a serotonin reuptake inhibitor, currently is used in treatment of obesity. The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects. We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman. We hypothesize that sibutramine, through its effect on neurotransmitters, may induce antidiuretic hormone secretion and lead to a syndrome of inappropriate antidiuretic hormone secretion. We advise careful monitoring of water-electrolytic balance during sibutramine therapy.
